Advertisement
Advertisement
HALO
Halozyme Therapeutics, Inc.
112.89
USDSponsored
-1.01
-0.89%
Sep 28, 15:59 UTC -4
Closed
Pre-Market
112.80
-0.09
-0.08%
HALO Earnings Reports
Positive Surprise Ratio
HALO beat 32 of 43 last estimates.
74%
Next Report
Date of Next Report
Nov 02, 2026
Estimate for Q3 26 (Revenue/ EPS)
$499.38M
/$2.39
Implied change from Q2 26 (Revenue/ EPS)
+3.82%
/+5.29%
Implied change from Q3 25 (Revenue/ EPS)
+40.96%
/+38.95%
Halozyme Therapeutics, Inc. earnings per share and revenue
On Aug 06, 2026, HALO reported earnings of 2.27 USD per share (EPS) for Q2 26, beating the estimate of 1.87 USD, resulting in a 21.75% surprise. Revenue reached 481.00 million, compared to an expected 415.64 million, with a 15.72% difference. The market reacted with a +20.24% price change (close before vs. close after earnings).
Looking ahead to Q3 26, 6 analysts forecast an EPS of 2.39 USD, with revenue projected to reach 499.38 million USD, implying an increase of 5.29% EPS, and increase of 3.82% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Abivax SA - ADR
Report Date
Sep 21, 2026 For Q2 26
Estimate
-$1.82
Actual
-$2.09
Surprise
-14.47%
AnaptysBio, Inc. Common Stock
Report Date
Sep 21, 2026 For Q2 26
Estimate
$0.00
Actual
$5.11
Surprise
>+10,000.00%
BlossomHill Therapeutics, Inc. Common Stock
Report Date
Sep 18, 2026 For Q2 26
Estimate
-$1.03
Actual
-$8.75
Surprise
-746.56%
Vogenx Inc Common Stock
Report Date
Sep 17, 2026 For Q2 26
Estimate
-$0.07
Actual
-$0.07
Surprise
+1.96%
AYTU BioPharma, Inc. Common Stock
Report Date
Sep 22, 2026 For Q4 26
Estimate
-$0.33
Actual
-$0.05
Surprise
+84.92%
Neuphoria Therapeutics Inc. Common Stock
Report Date
Sep 18, 2026 For Q4 26
Estimate
-$0.57
Actual
-$0.95
Surprise
-66.32%
NewcelX Ltd. Ordinary Shares
Report Date
Sep 18, 2026 For Q2 26
Estimate
-$0.54
Actual
-$0.96
Surprise
-77.58%
FAQ
What were Halozyme Therapeutics, Inc.'s earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, Halozyme Therapeutics, Inc. reported EPS of $2.27, beating estimates by 21.75%, and revenue of $481.00M, 15.72% above expectations.
How did the market react to Halozyme Therapeutics, Inc.'s Q2 2026 earnings?
The stock price moved up 20.24%, changed from $85.76 before the earnings release to $103.12 the day after.
When is Halozyme Therapeutics, Inc. expected to report next?
The next earning report is scheduled for Nov 02, 2026.
What are the forecasts for Halozyme Therapeutics, Inc.'s next earnings report?
Based on 6
analysts, Halozyme Therapeutics, Inc. is expected to report EPS of $2.39 and revenue of $499.38M for Q3 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.